GLP1R and intestinal obstruction: At the same time, the absence of a harmful signal for other GLP-1 receptor agonists and SGLT2 inhibitors, and the potentially protective association for liraglutide, provide reassurance that these agents can generally be used without substantially increasing intestinal obstruction risk.